[1]
Rezza, G. et al. 2025. Nirsevimab: a change of paradigm in the prophylaxis of Respiratory Syncytial Virus disease among infants. Annali di Igiene Medicina Preventiva e di Comunità€. 37, 5 (Jun. 2025), 684–688. DOI:https://doi.org/10.7416/ai.2025.2712.